Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Abstract

Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness. With an increasing number of glaucoma patients and disease progression despite treatment, it is paramount to develop new and effective therapeutics. Emerging new candidates are the receptor agonists of the incretin hormone glucagon-like-peptide-1 (GLP-1), originally used for the treatment of diabetes. GLP-1 receptor (GLP-1R) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., Alzheimer’s disease, Parkinson’s disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and AMD). However, there are currently very few studies investigating the protective effects of GLP-1R agonists in the treatment of specifically glaucoma. Based on a literature search on PubMed, the Cochrane Library, and ClinicalTrials.gov, this review aims to summarize current clinical literature on GLP-1 receptor agonists in the treatment of neurodegenerative diseases to elucidate their potential in future anti-glaucomatous treatment strategies.

Introduction

Glaucoma is one of the most common neurodegenerative eye diseases and the leading cause of irreversible blindness. It is estimated to affect ∼112 million people worldwide by 2040 (Tham et al., 2014). Glaucoma is characterized by the progressive and irreversible loss of retinal ganglion cells, the output neurons of the retina. There are three primary risk factors for glaucoma; increasing age, genetic risk and elevated intraocular pressure (IOP). Elevated IOP is strongly associated with disease progression in ∼60% of patients, but all available anti-glaucomatous therapies (pharmacological and surgical) exclusively target IOP (Kolko, 2015, 2017; Kolko et al., 2015; Kalouda et al., 2017; Quigley, 2019). The number of glaucoma cases associated with an actually elevated IOP varies significantly across glaucoma subtypes, and many glaucoma patients progress to blindness despite low IOPs and/or are refractory to IOP-lowering treatments (Dielemans et al., 1994; Heijl et al., 2002; Topouzis and Anastasopoulos, 2007; Cedrone et al., 2008; Peters et al., 2013; Ho and Wong, 2019). Therefore, there is an urgent unmet need to explore new therapies targeting mechanisms of glaucomatous neurodegeneration in addition to IOP reduction. One such important new route of study in glaucoma, and the focus of this review, may be the glucagon-like peptide 1 (GLP-1).

Glucagon-like peptide 1 (GLP-1) is an incretin hormone that, like its fellow incretin hormone GIP (glucose-dependent insulinotropic polypeptide), stimulates a decrease in blood glucose levels after nutrient intake. GLP-1 achieves the decrease in blood glucose levels by potentiating glucose-induced insulin secretion (the “incretin”-effect), improving insulin sensitivity and inhibiting glucagon release. Furthermore, GLP-1 regulates weight and satiety and delays gastric emptying (Gutniak et al., 1992; Drucker, 2018; Yildirim Simsir et al., 2018). The first agents targeting GLP-1 receptor (GLP-1R) signaling were developed to optimize the treatment of type 2 diabetes mellitus (T2D) as an adjunct to metformin when therapeutic goals where not met (Yildirim Simsir et al., 2018). The first GLP-1R agonists received FDA-approval in 2005 and included exenatide. Subsequently, many different GLP-1R agonists were developed and approved, including: extended release exenatide (exenatide XR), liraglutide, lixisenatide, dulaglutide, and semaglutide (Table 1). Although all GLP-1R agonists are effective in stabilizing blood glucose levels, glycated hemoglobin (HbA1c), cholesterol levels, insulin sensitivity, and several other beneficial aspects of metabolism in T2D patients (Courrèges et al., 2008; Patel et al., 2014; Jinnouchi et al., 2015; Rizvi et al., 2015; Rizzo et al., 2015, 2016), drug administration has been challenging. Until recently, the treatments had to be administered subcutaneously (Table 1). In September 2019, the first oral GLP-1R agonist for T2D was approved by FDA (Davies et al., 2017; Aroda et al., 2019; Husain et al., 2019; Mosenzon et al., 2019; Pieber et al., 2019; Pratley et al., 2019; Rodbard et al., 2019; Rosenstock et al., 2019; The U.S. Food and Drug administration, 2019; Zinman et al., 2019a; Yabe et al., 2020; Yamada et al., 2020; Khoo and Lin, 2021). With its great beneficial systemic effects and promising results from previous randomized clinical trials with injectable semaglutide, the oral GLP-1R agonist, Rybelsus^®, also seem to be a promising and convenient anti-obesity treatment option (Khoo and Lin, 2021).

Glucagon-like peptide 1 (GLP-1) agonists not only exert a beneficial systemic effect, but also cross the blood-brain barrier (Kastin et al., 2002; Secher et al., 2014; Yildirim Simsir et al., 2018). In this context, GLP-1R agonists have been shown to affect the central nervous system and exhibit neuroprotective properties in animal models of several neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, stroke, diabetic retinopathy, and ocular hypertension (McClean et al., 2011; Hao et al., 2012; Fan et al., 2014; Gonçalves et al., 2016; Zhang et al., 2018, 2019; Basalay et al., 2019; Yang et al., 2019; Chang et al., 2020; Ramos et al., 2020; Ren et al., 2020; Sterling et al., 2020; Zhai et al., 2020). The potential neuroprotective properties of GLP-1R agonists have also been demonstrated in clinical trials, with Novo Nordisk currently running a phase III clinical trial of oral semaglutide as a potential treatment option for Alzheimer’s disease in the announced EVOKE trial program (NCT04777409, NCT04777396).

In addition to GLP-1R agonists, orally administrated DPP4-inhibitors, e.g., sitagliptin and saxagliptin, which are known to potentiate the effect of endogenous GLP-1 by inhibiting its degradation, have also been clinically studied as protective agents against retinopathy (Chung et al., 2016), Alzheimer’s disease (Isik et al., 2017), and Parkinson’s disease (Svenningsson et al., 2016) in T2D patients, although DPP4-inhibitors cannot cross the blood-brain barrier (Mousa and Ayoub, 2019).

Recently, a registry-based case-control study of 1,961 patients also associated the use of GLP-1R agonists with a reduced risk of glaucoma (Sterling et al., 2021), strongly supporting further research into the use of agents that increase GLP-1R signaling as anti-glaucomatous treatment strategies. Accordingly, previous studies of oral antidiabetics and insulin have also been proposed for the treatment of glaucoma as well as other ocular conditions such as age-related macular degeneration (AMD) (Ott et al., 2014; Lin et al., 2015, 2017; Chung et al., 2016, 2019; Maleškić et al., 2017; Douros et al., 2018; Kim et al., 2018; Li et al., 2018; Vilsbøll et al., 2018; Wang et al., 2018; Brown et al., 2019; Chen et al., 2019; Fan et al., 2020; Gaborit et al., 2020; Blitzer et al., 2021; Sterling et al., 2021). The present review aims to summarize current literature on antidiabetics in the treatment of neurodegenerative diseases with a special focus on GLP-1R agonists and glaucoma.

Method of Literature Search

PubMed and the Cochrane Library were searched in April 2021 (Figure 1). The search was not limited to a specific language. However, mainly clinical studies and clinically inclined reviews were included as core sources. In addition, the Cochrane Library was screened for relevant Cochrane reviews only. MeSH-controlled vocabulary terms and related keywords were combined using appropriate Boolean operators to find literature either investigating or discussing incretin-based drugs (GLP-1R agonists and DPP4-inhibitors) for the treatment of neurodegenerative diseases, particularly glaucoma, diabetic retinopathy, AMD, Alzheimer’s disease, Parkinson’s disease, stroke and neuropathy. Search words included: GLP-1, Glucagon-Like Peptide 1, semaglutide, oral semaglutide, Rybelsus, Ozempic, liraglutide, lixisenatide, dulaglutide, albiglutide, exenatide, DPP4 inhibitor, dipeptidyl phosphatase 4 inhibitor, sitagliptin, antidiabetics, metformin, insulin, type 2 diabetes, diabetes, diabetes mellitus, neurodegenerative diseases, glaucoma, AMD, age-related macular degeneration, diabetic retinopathy, elderly, Alzheimer, dementia, cognitive impairment, Alzheimer’s Disease, Parkinson, Parkinson’s Disease, stroke, neuropathy. The reference lists of all core sources were searched for additional references. Completed and ongoing trials examining the role of GLP-1R agonists, especially semaglutide, in the treatment of glaucoma, AMD, Alzheimer’s, and Parkinson’s disease, were searched on the public clinical trial registry clinicaltrials.gov (NCT04777409, NCT04777396, NCT03811561, NCT01843075, NCT04232969, NCT03659682, NCT02953665, NCT04305002, NCT03439943, NCT04269642, NCT04154072, NCT02673931, NCT02829502, NCT02838589, NCT00418288, NCT00256256, NCT03948347, NCT03287076, NCT02684578, NCT05035095). Completed clinical trials with unknown status, no recent updates, no public or published results, and no relevance to the subject of the current review were excluded.

FIGURE 1

Results and Discussion

Oral Semaglutide Has Great Potential for the Prevention of Retinal Neurodegeneration

There is a demonstrated neuroprotective effect of GLP-1R agonists in both the retina and brain in preclinical studies of ocular hypertension, diabetic retinopathy, Alzheimer’s disease, Parkinson’s disease, stroke, neuropathy, and several other neurodegenerative diseases (Kastin et al., 2002; McClean et al., 2011; Hao et al., 2012; Fan et al., 2014; Secher et al., 2014; Gonçalves et al., 2016; Zhang et al., 2018, 2019; Basalay et al., 2019; Yang et al., 2019; Chang et al., 2020; Ramos et al., 2020; Ren et al., 2020; Sterling et al., 2020; Zhai et al., 2020). In the retina, GLP-1R agonists have specifically protected retinal ganglion and glia cells, such as the Müller glia, from various stresses (Hao et al., 2012; Fan et al., 2014; Gonçalves et al., 2016; Yang et al., 2019; Ramos et al., 2020; Ren et al., 2020; Sterling et al., 2020) (Figure 2).

FIGURE 2

One of the most promising and effective GLP-1R agonists is semaglutide (Tables 1, 2) (Trujillo et al., 2021), which until September 2019 was only available as an injectable formulation. Semaglutide is also being tested in trials against diabetic eye diseases expected to end in 2027 (NCT03811561; the FOCUS trial). Now, with its ability to be administered orally, semaglutide offers great opportunities in the treatment of T2D as well as other potential disease groups. Semaglutide was designed from the backbone of another GLP-1R agonist, liraglutide, which has been tested as a prospective neuroprotective treatment option against dementia (Femminella et al., 2019; Evaluate, 2020) (NCT01843075, the ELAD study). In addition, semaglutide; like dulaglutide and exenatide XR, were developed to act as a long-acting GLP-1 analog, replacing the previous subcutaneous injections once daily with once weekly administration, potentially improving patient adherence and convenience (Lau et al., 2015).

The safety and efficacy of semaglutide have been assessed in several phase II and III clinical trials (Marso et al., 2016a; Nauck et al., 2016; Ahrén et al., 2017; Aroda et al., 2017, 2019; Davies et al., 2017; Sorli et al., 2017; Ahmann et al., 2018; Kaku et al., 2018; Pratley et al., 2018, 2019; Rodbard et al., 2018, 2019; Seino et al., 2018; Husain et al., 2019; Lingvay et al., 2019; Mosenzon et al., 2019; Pieber et al., 2019; Rosenstock et al., 2019; Zinman et al., 2019a,b; Capehorn et al., 2020; Ji et al., 2020; Yabe et al., 2020; Yamada et al., 2020). Among these, there are 15 studies assessing the injectable semaglutide as part of the SUSTAIN trial series and 10 evaluating the newly approved oral semaglutide as part of the PIONEER trial program (Table 2). Through the SUSTAIN 1-10 (Marso et al., 2016a; Ahrén et al., 2017; Aroda et al., 2017; Sorli et al., 2017; Ahmann et al., 2018; Pratley et al., 2018; Rodbard et al., 2018; Lingvay et al., 2019; Zinman et al., 2019b; Capehorn et al., 2020) trials, the effect of injectable semaglutide, measured as reductions in glycated hemoglobin and bodyweight, was generally significantly better than treatment with DPP4-inhibitors (sitagliptin) (Ahrén et al., 2017; Seino et al., 2018; Ji et al., 2020), SGLT-2-inhibitors (canagliflozin) (Lingvay et al., 2019), long-acting insulin (insulin glargine) (Aroda et al., 2017), and other GLP-1R agonists [exenatide XR (Ahmann et al., 2018), dulaglutide (Pratley et al., 2018) and liraglutide (Capehorn et al., 2020)]. In the PIONEER 3 (Rosenstock et al., 2019) and 7 (Pieber et al., 2019) trials, oral semaglutide was also found to be superior to the DPP4-inhibitor sitagliptin. In addition, a retrospective database study estimated that patients’ persistence of injectable semaglutide treatment was significantly higher than treatment with dulaglutide, liraglutide and exenatide XR (Table 1) (Uzoigwe et al., 2021). Semaglutide has also shown promise as an effective anti-obesity treatment option. In a randomized clinical trial, a dose of 2.4 mg injectable semaglutide weekly in subjects with or without weight-related complication, semaglutide, along with lifestyle interventions, was associated with sustained as well as clinically relevant reduction in body weight (Khoo and Lin, 2021). In 2021, Novo Nordisk launched the OASIS trial expected to end in 2023 assessing the beneficial effects and safety-profile of 50 mg daily semaglutide compared to placebo (NCT05035095).

When comparing oral semaglutide with injectable GLP-1R agonists as in the PIONEER 4 trial (Pratley et al., 2019), oral semaglutide appears to be an even better option than injectable alternatives. In addition, daily oral semaglutide was found to be ranked as the best GLP-1R agonist to reduce cardiovascular death and death from any cause when indirectly compared with injectable semaglutide, liraglutide, lixisenatide, dulaglutide, albiglutide, exenatide and placebo (Alfayez et al., 2020). Compared to subcutaneously injected semaglutide, a phase II trial showed that oral semaglutide was equally effective in improving HbA1c and body weight for the T2D patients included in the trial (Davies et al., 2017).

Oral semaglutide is also likely to be more cost-effective than other existing GLP-1R agonists in the treatment of T2D patients (Hansen et al., 2020). Across the PIONEER trials, the most common adverse effects of oral semaglutide were related to the gastrointestinal tract, similar to the injectable GLP-1R agonists, and manifested as: vomiting, diarrhea and nausea (Seidu et al., 2021). In addition, oral semaglutide was not associated with severe cardiovascular outcomes or further kidney impairment in patients with renal dysfunction (Mosenzon et al., 2019). This further supports oral semaglutide as effective despite long-standing T2D and comorbidities. Thus, oral semaglutide appears to be the most effective and convenient option compared to other GLP-1R agonists, DPP4-inhibitors, and second-line antidiabetic agents. Novo Nordisk also recently started recruiting participants to the EVOKE trial program (phase III) expected to end in 2024, in which the effectiveness of oral semaglutide in the treatment of early Alzheimer’s disease will be assessed by measuring changes in clinical dementia rating, daily activity, mild cognitive impairment and mini-mental state examinations and other secondary outcome measures (NCT04777409, NCT04777396). Furthermore, as semaglutide is the only GLP-1R agonist that can be administrated as both an oral and injectable formulation, the selection of the most convenient mode of administration can be made on an individual level to best suit the patients’ preferences and needs. Given the potential neuroprotective and insulin sensitivity-regulating effects of compounds that increase GLP-1R signaling, semaglutide appears to be a promising candidate for further investigation as a novel add-on compound in the treatment of neurodegenerative diseases, such as glaucoma.

Glucagon-Like Peptide 1 Agonists and Other Antidiabetic Agents as a Potential Treatment for Glaucoma

Several antidiabetic compounds have shown potential for glaucoma treatment (Lin et al., 2015; Maleškić et al., 2017; Sterling et al., 2021) (Table 3). In support of this, several studies have suggested that diabetes mellitus is a risk factor for glaucoma (Oshitari et al., 2007; Chopra et al., 2008; Welinder et al., 2009; Zhou et al., 2014; Horwitz et al., 2016; Jung et al., 2018; Hanyuda et al., 2020). Thus, it raises the question of whether glaucoma may be associated with retinal insulin desensitization (Agostinone et al., 2018) as well as insulin desensitization of the brain as associated with Alzheimer’s and Parkinson’s disease (Faiq et al., 2014; Dada, 2017; Faiq and Dada, 2017). However, the mechanistic link and relationship between glaucoma and T2D still needs further analysis and requires further elucidation (Tielsch et al., 1995; Ellis et al., 2000; Quigley, 2009).

Metformin

Studies conducted by Lin et al. (2015) have shown that patients with T2D had a reduced risk of developing glaucoma when exposed to antihyperglycemic agents, in particular metformin, which was associated with a reduced risk of developing open-angle glaucoma. A later observational study also associated the use of metformin with a reduced risk of both glaucoma and diabetic retinopathy (Maleškić et al., 2017). The use of metformin has also been linked with a lower risk of developing other neurodegenerative eye conditions, such as AMD (Brown et al., 2019; Chen et al., 2019; Blitzer et al., 2021), and diabetic retinopathy (Maleškić et al., 2017; Li et al., 2018; Fan et al., 2020) (Table 4). The effects of metformin on AMD progression have not yet been directly investigated. However, there is currently an ongoing trial (scheduled for completion in 2023) that assesses the use of metformin to minimize geographic atrophy progression in AMD patients (NCT02684578).

DPP4-Inhibitors

In addition, with respect to other ocular conditions and the use of antidiabetic drugs, DPP4-inhibitors have been suggested to exert a protective role in the progression of diabetic retinopathy (Ott et al., 2014; Chung et al., 2016, 2019; Kim et al., 2018). In a cohort study, DPP4-inhibitors appeared to protect against diabetic retinopathy progression, independent of their glucose-lowering effect (Chung et al., 2016). Another population-based study in South Korea comparing the use of DPP4-inhibitors with other oral glucose lowering agents (sulfonylurea, thiazolidinedione, and metformin) showed that the overall risk of diabetic retinopathy events was not increased (Kim et al., 2018). These findings are supported by a small double-blinded, placebo-controlled trial in 50 T2D patients, where 6 weeks of treatment with the DPP4-inhibitor, saxagliptin, increased vasodilation capacity and decreased retinal capillary blood flow (Ott et al., 2014). Another recent cohort study showed that the combination of metformin with DPP4-inhibitors had a strong beneficial effect against non-proliferative diabetic retinopathy (NPDR) (Fan et al., 2020). Moreover, the same study showed that the use of sulfonylurea instead of DPP4-inhibitors in combination with metformin increased the risk of NPDR (Fan et al., 2020). Thus, several clinical studies have linked the use of DPP4-inhibitors to either a reduced odds of diabetic retinopathy or a reduced risk of diabetic retinopathy progression (Ott et al., 2014; Kim et al., 2018; Wang et al., 2018; Chung et al., 2019; Fan et al., 2020).

Glucagon-Like Peptide 1 Agonists

Sterling et al. (2021) linked the exposure to GLP-1R agonists (i.e., dulaglutide, liraglutide, lixisenatide, exenatide, and semaglutide) to a low risk of developing open-angle glaucoma (Sterling et al., 2021). However, previous studies have raised concern that treatment with GLP-1R agonists may increase the risk of diabetic retinopathy, making them less favorable to be used against diabetic eye complications (Diabetes Control and Complications Trial Research Group, Nathan et al., 1993; No authors listed, 1998, 1999; Aiello and Dcct/Edic Research Group, 2014; Green et al., 2015; Marso et al., 2016b; Jingi et al., 2017; Tang et al., 2018; Bain et al., 2019; Lim et al., 2019; Bethel et al., 2021). Nevertheless, this effect of GLP-1R agonists is most likely caused by a rapid decrease in patients’ blood glucose levels as discussed later (Vilsbøll et al., 2018; Bain et al., 2019; Lim et al., 2019). The AngioSafe 1 study, which is also designed to clarify the association between exposure to GLP-1R agonists and diabetic retinopathy through clinical and preclinical study designs found no risk for severe diabetic retinopathy when patients were treated with GLP-1R agonists, and no effect of GLP-1R agonists on angiogenesis (Gaborit et al., 2020). In prospect, the effect of GLP-1R agonist exposure on severe diabetic retinopathy should be further elucidated in the ongoing AngioSafe 2 study (NCT02671864). Another phase III interventional study by Novo Nordisk, the FOCUS trial, also investigates the long-term effects of injectable semaglutide in diabetic eye diseases (NCT03811561).

Diabetic Retinopathy and Glucagon-Like Peptide 1 Agonists

Previous studies, including the DCCT, SUSTAIN-6, LEADER and TECOS trials, have linked exposure to incretin-based therapies and other hypoglycemic agents (i.e., insulin, injectable semaglutide, liraglutide, and oral sitagliptin) to the exacerbation of pre-existing retinopathy (Diabetes Control and Complications Trial Research Group, Nathan et al., 1993; No authors listed, 1998, 1999; Aiello and Dcct/Edic Research Group, 2014; Green et al., 2015; Marso et al., 2016a,b; Jingi et al., 2017; Tang et al., 2018; Bain et al., 2019; Lim et al., 2019; Bethel et al., 2021). For example, the SUSTAIN-6 trial showed that the risk of retinopathy events was increased during the first 2 months of treatment with injectable semaglutide. Nevertheless, a post hoc analysis across the SUSTAIN trials (Marso et al., 2016a; Ahrén et al., 2017; Aroda et al., 2017; Sorli et al., 2017; Ahmann et al., 2018; Kaku et al., 2018; Pratley et al., 2018; Rodbard et al., 2018; Seino et al., 2018; Lingvay et al., 2019; Zinman et al., 2019b; Capehorn et al., 2020; Ji et al., 2020) associated the increased risk of diabetic retinopathy with being limited to the early stages of treatment and mainly caused by rapid improvements in glycemic control, i.e., not a direct adverse effect of semaglutide (Vilsbøll et al., 2018). As part of the AngioSafe 1 study, both an observational and interventional phase IV study of patients with T2D showed that GLP-1R agonists did not increase the risk for severe diabetic retinopathy (Gaborit et al., 2020). This was further supported by another study comparing GLP-1R agonists to thiazolidinedione and long-acting insulin where GLP-1R agonists did not increase the risk of diabetic retinopathy over an average treatment time of less than 1 year (Wang et al., 2018). Accordingly, a cohort study found no association between the exposure to GLP-1R agonists and diabetic retinopathy, and in fact GLP-1R agonists were found to even decrease the risk of diabetic retinopathy by 33% when compared to new-users of insulin (Douros et al., 2018). Over a longer period of time, the progression of diabetic retinopathy after intensified glycemic control has also been demonstrated to be transient and reversible (Aiello and Dcct/Edic Research Group, 2014). The intensive glycemic control of diabetic patients appears to reduce both the risk of progression and the onset of diabetic retinopathy (Aiello and Dcct/Edic Research Group, 2014 with conventional antidiabetic treatments. Thus, the association between hypoglycemic agents and the exacerbation of diabetic retinopathy remains uncertain, and the early worsening is likely due to rapid lowering of blood glucose and intensified glycemic control, which, in the long run, also appears to be beneficial (Aiello and Dcct/Edic Research Group, 2014; Jingi et al., 2017; Tang et al., 2018; Vilsbøll et al., 2018; Wang et al., 2018; Bethel et al., 2021). A recent meta-regression analysis of GLP-1R agonist cardiovascular outcome trials (LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, and PIONEER-6 trials) has suggested that clinicians should consider the status of diabetic retinopathy in patients before initiating treatment with GLP-1R agonists (Bethel et al., 2021). In summary, the risk of diabetic retinopathy does not seem to be increased with the use of GLP-1R agonists and is being further investigated in ongoing trials (NCT02671864, NCT03811561). Thus, the patient’s retinopathy status must be determined before initiating treatment with incretin-based therapies as the GLP-1R agonists.

What Are the Possible Concerns About Glucagon-Like Peptide 1 Agonists as Potential Treatments for Glaucoma?

If GLP-1R agonists are to be used in the treatment of glaucoma patients, their retinopathy status must be determined before start of treatment. The most common type of glaucoma is primary open-angle glaucoma, with the typical patients being elderly and often underweight (Klein et al., 1992; Leske et al., 1994; Wensor et al., 1998; Jonasson et al., 2003; Iwase et al., 2004; de Voogd et al., 2005; Na et al., 2020). Accordingly, the appetite suppressant and weight loss effects of GLP-1R stimulation (Khoo and Lin, 2021) should be considered in potential trials with GLP-1R agonists as therapeutic agents for the treatment of glaucoma. Consideration should also be given as oral semaglutide has been associated with greater discontinuation of treatment in patient groups aged 65 years or older (Aroda et al., 2020). The most common reason stated for patients discontinuing oral semaglutide has been its mild to moderate gastrointestinal adverse effects, especially nausea, which is experienced by up to 50% of patients (Filippatos et al., 2014; Pratley et al., 2019; Zinman et al., 2019a; Aroda et al., 2020; Evaluate, 2020). Therefore, premature discontinuation of oral semaglutide due to adverse effects turn out to be only a few percent higher than its injectable alternatives. In the PIONEER-4 trial, 11% of the patients using oral semaglutide discontinued treatment because of adverse effects compared to 9% of the patients using subcutaneous liraglutide (Pratley et al., 2019). Another phase II interventional study found that premature cessation of treatment due to adverse effects was also higher for oral semaglutide than injectable semaglutide (Warren et al., 2018). However, this study as well as other studies (Davies et al., 2017; Warren et al., 2018; Aroda et al., 2020; Wright and Aroda, 2020) reported that both oral and injectable semaglutide were mostly discontinued due to gastrointestinal adverse effects. This together with the fact that patients showed treatment satisfaction in favor of injectable semaglutide rather than, e.g., injectable liraglutide in the SUSTAIN-10 trial (Capehorn et al., 2020), suggests that the higher proportion of patients discontinuing oral semaglutide treatment may be due to patients having to administer oral semaglutide once every day versus once a week with injectable semaglutide, making compliance for oral semaglutide more difficult and more expensive. Therefore, premature discontinuation of oral semaglutide may be due to the fact that elderly patients may be weaker, prefer treatment once a week, and are more susceptible to gastrointestinal intolerance (Newton, 2005) combined with baseline comorbidities that complicate continuation of treatment. Premature discontinuation of treatment due to adverse effects may also be simply due to the dosage of oral semaglutide and the rate of dose escalation. For instance, a dose of 7 mg oral semaglutide in the PIONEER 8 trial caused a lower percentage of patients discontinuing treatment compared to 14 mg oral semaglutide (7 mg: 9% and 14 mg: 13%, respectively) (Zinman et al., 2019a). Similar to the conventional subcutaneously administrated GLP-1R agonists, another study found that slow dose escalation of oral semaglutide resulted in a lower proportion of patients discontinuing treatment (Davies et al., 2017). Furthermore, the adverse effects of oral semaglutide tend to exacerbate as the dose is increased (Wright and Aroda, 2020). This suggests that the premature discontinuation of oral semaglutide in trials may also be due to patients’ expectations at the start of treatment and lack of counseling that effects such as nausea are frequent experiences that typically disappear over time. However, a recent Japanese health-related quality of life assessment of the PIONEER-10 trial showed that patients tended to be more satisfied when treated with oral semaglutide than with injectable dulaglutide (Ishii et al., 2021). Patients treated with oral semaglutide were also more adherent to the treatment (Ishii et al., 2021). This suggests that oral GLP-1 receptor agonists, compared to injectable GLP-1 receptor agonists, result in greater patient satisfaction and treatment persistence.

In summary, current knowledge about the potential disadvantages of GLP-1R agonist drugs is few compared to the potential beneficial neuroprotective properties. Semaglutide, in both injectable and oral formulations, appears to be a promising potential GLP-1R agonist in combination with conventional IOP-lowering agents to decrease the rate of glaucoma worsening. However, it would be wise to assess retinopathy status, patients’ BMI, age and preference for weekly subcutaneous injections or daily oral administrations as well as the dose before starting treatment.

Glucagon-Like Peptide 1 Agonists Show Neuroprotective Properties in the Treatment of Other Neurodegenerative Diseases

Glucagon-like peptide 1 (GLP-1) and GLP1R agonists have been associated not only with neuroprotection in the retina but also in the brain in various animal models of neurodegenerative diseases (Zhang et al., 2018, 2019; Basalay et al., 2019; Yang et al., 2019; Chang et al., 2020; Zhai et al., 2020). The promising preclinical results have now paved the way for evaluating the use of GLP-1R agonists in clinical studies with neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, stroke, and diabetic neuropathy. The neuroprotective effect of GLP-1R agonists is that it can either directly/locally cause neuroprotection by acting on neuronal tissue or indirectly/systemically cause neuroprotection by improving glycemic control and treating existing insulin resistance (Figure 3) (Fiory et al., 2019; Femminella et al., 2021).

FIGURE 3

Alzheimer’s Disease

Several early studies have identified the presence of cognitive impairment in patients with T2D (Perlmuter et al., 1984; Helkala et al., 1995; Vanhanen et al., 1999), and T2D has been recognized as a risk factor for the development of Alzheimer’s disease (Janson et al., 2004). In addition, Alzheimer’s disease has also been directly linked to insulin resistance (Neth and Craft, 2017; Arnold et al., 2018; Hölscher, 2019; Kellar and Craft, 2020), even in the absence of concomitant diabetes (Schrijvers et al., 2010). In this case, peripheral insulin resistance was associated with decreased hippocampal glucose metabolism and lower volume of gray matter in a population of non-diabetic patients with Alzheimer’s disease (Femminella et al., 2021). Similarly, patients with cognitive impairment and Alzheimer’s disease have been shown to improve in memory, attention, mental tasks, cognition, and brain activation following insulin treatment, both intravenously and intranasally (Craft et al., 1996, 1999, 2003, 2012, 2017; Kern et al., 2001; Reger et al., 2006, 2008a,b; Claxton et al., 2015; Femminella et al., 2021; Hallschmid, 2021). Although these are promising results, evidence for a protective role for insulin remains low, and a recent Cochrane review from 2017 found no protective or preventive association between cognitive impairment and the use of antidiabetic T2D treatment strategies (Areosa Sastre et al., 2017) (i.e., metformin, insulin, repaglinide, glibenclamide, glimepiride, rosiglitazone, gliclazide, perindopril-indapamide). An aspiring novel take on insulin regulation is the administration of GLP-1R agonists, as these both regulate insulin sensitivity in the brain (Sandoval and Sisley, 2015) and possibly exert direct neuroprotective effects (Figure 3).

Besides preclinical studies pointing toward a potential use of GLP-1R agonists in the treatment of Alzheimer’s (McClean et al., 2011; Chang et al., 2020), a recent post hoc analysis led by Novo Nordisk comprising 15,820 patients with T2D, the use of the GLP-1R agonists liraglutide and semaglutide was also associated with a 53% significantly lower risk of developing dementia (Ballard et al., 2020). These findings have led to the initiation of the EVOKE trial program in 2021, which will enlighten a potential neuroprotective effect of oral semaglutide in the future. Previously, a neuroprotective effect of GLP-1R agonists has also been supported by long-term treatment with another GLP-1R agonist, dulaglutide, which reduced cognitive impairment in patients with T2D compared to placebo (NCT01394952; the REWIND trial) (Cukierman-Yaffe et al., 2020). 6-months of treatment with the GLP-1R agonist liraglutide (Victoza^®) in Alzheimer’s disease patients was found to prevent declines in cerebral glucose metabolism, which is associated with synaptic dysfunction, cognitive impairment, and progression of the disease (Gejl et al., 2016) (Table 5). 12 weeks liraglutide-treatment of patients at high risk for dementia was also shown to increase connectivity in the default mode network supporting the fact that GLP-1R agonists may reduce or hinder the progression of Alzheimer’s disease (Watson et al., 2019). Supporting the hypothesis that increased GLP-1R signaling potentially promotes neuroprotection, DPP4-inhibitors are also associated with improved cognitive function (Isik et al., 2017; Xue et al., 2020). The use of GLP-1R agonists in Alzheimer’s disease also appears to be beneficial in an as yet unpublished multicenter, 12-month, phase II UK trial (NCT01843075, the ELAD-study), which evaluates liraglutide as a potential therapeutic agent in Alzheimer’s patients with mild dementia (Femminella et al., 2019). Results from the ELAD-study, presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD) 2020, showed that daily injections of liraglutide improved secondary outcomes of the study, i.e., the volume of gray matter and the cognitive function measured as improvements in Alzheimer’s Disease Assessment Scale (ADAS) scores (Evaluate, 2020). Thus, the use of GLP-1R agonists and DPP4-inhibitors has been reported to prevent cognitive impairment in several clinical studies (Gejl et al., 2016; Isik et al., 2017; Mansur et al., 2017; Watson et al., 2019; Ballard et al., 2020; Cukierman-Yaffe et al., 2020; Xue et al., 2020).

In contrast, a recent pilot study could not conclude any neuroprotective property of the GLP-1R agonist exenatide, other than a reduced level of Aβ (NCT01255163) (Mullins et al., 2019). However, the lack of significant results favoring a neuroprotective effect of GLP-1R agonists may be due to early business-related withdrawal of sponsor support (Mullins et al., 2019). Thus, there is evidence in favor of a neuroprotective effect of GLP-1R agonists in Alzheimer’s disease, which will hopefully be better elucidated in ongoing clinical trials such as the EVOKE trial program.

Parkinson’s Disease

Clinical studies on GLP-1R agonists in Parkinson’s disease have focused on the GLP-1R agonist exenatide, which has yielded many promising results (Aviles-Olmos et al., 2013, 2014; Athauda et al., 2017, 2018, 2019a,b; Brauer et al., 2020) (Table 6). These notable developments have even led to the initiation of a phase III clinical trial with exenatide (Bydureon^®) as an antiparkinsonian agent, launched in the beginning of 2020 (NCT04232969). The observed neuroprotective effects of GLP-1R agonists can be attributed to a possible mechanistic link between Parkinson’s disease and diabetes. Low insulin sensitivity has, similar to Alzheimer’s disease, been associated with an increased risk of developing Parkinson’s disease (Athauda and Foltynie, 2016). In addition, insulin is expected to have a decisive influence on the dopaminergic system (Fiory et al., 2019). Death of dopaminergic neurons in the substantia nigra pars compacta and changes in striatal nuclei in patients with Parkinson’s disease have been correlated with remarkable changes in structures involved with insulin signaling (Fiory et al., 2019). A possible mechanism behind the properties of exenatide in the study by Athauda et al. (2019a) was suggested to be a normalization of brain insulin signaling and an involvement of Akt signaling pathways. This was supported through electrochemiluminescence assay quantifications of proteins related to insulin signaling (i.e., phosphorylated forms of Akt) from neuronal-derived exosomes harvested from peripheral blood samples of Parkinson’s patients who had participated in the study (NCT01971242) (Athauda et al., 2019a).

A recent population-based cohort study by Brauer et al. (2020) also found evidence of a lower incidence of Parkinson’s disease in diabetic short-term and long-term users of GLP-1R agonists and DPP4-inhibitors (Brauer et al., 2020), suggesting beneficial assets of anti-diabetic drugs in the fight against Parkinson’s disease. This finding has been confirmed by other studies in which subcutaneous administration of exenatide to randomly assigned Parkinson’s patients was associated with greatly improved outcome measures that assessed the severity of motor symptom (Aviles-Olmos et al., 2013, 2014; Athauda et al., 2017, 2018). Motor function of Parkinson’s patients who have previously been exposed to exenatide has been shown to improve even 12 months after terminated treatment (Aviles-Olmos et al., 2014). Furthermore, exenatide appears to both suppress motor impairments (i.e., dyskinesia) and improve cognitive function of patients with Parkinson’s disease (Aviles-Olmos et al., 2013; Athauda et al., 2017). In addition, a post hoc analysis further revealed that exenatide improved a wide range of non-motor symptoms (i.e., mood, depression) in patients with Parkinson’s disease compared to placebo (Athauda et al., 2018). Concerning the treatment of Parkinson’s patients with GLP-1R agonists, there seems to be one compelling aspect regarding effectiveness of the treatment, and that is that the agonists should be administered as early as possible after diagnosis, as increasing age and disease duration over 10 years is associated with less effective response to exenatide treatment (Athauda et al., 2019b).

The effects of other GLP-1R agonists in the treatment of patients with Parkinson’s disease are also in line to be elucidated. A phase II study is currently investigating the neuroprotective effects of injectable semaglutide in 270 Parkinson’s patients in a double-blinded, placebo-controlled design (NCT03659682). Also, liraglutide (NCT02953665), lixisenatide (NCT03439943), exenatide (NCT04305002), sustained release exenatide – PT320 (NCT04269642) and a pegylated form of exenatide, NLY01 (NCT04154072), are all undergoing clinical investigation in Parkinson’s disease.

While GLP-1R agonists show promising results, there is a need to further investigate the neuroprotective effects of DPP4-inhibitors in Parkinson’s patients (Svenningsson et al., 2016; Brauer et al., 2020; Ece Bayram and Irene Litvan, 2020). Nevertheless, the numerous previous studies of exenatide combined with the initiation of a phase III clinical trial of exenatide, combined with ongoing trials, undeniably provide a promising basis for the prospective neuroprotective use of GLP-1R agonists in Parkinson’s disease.

Stroke

Stroke is associated with cognitive dysfunction (O’Brien et al., 2003), glaucoma (Lee et al., 2018; Rim et al., 2018), and secodary neurodegeneration (Ong et al., 2017). Several preclinical studies have observed GLP-1R agonists as neuroprotective compounds in rodent stroke models (Basalay et al., 2019; Yang et al., 2019), and GLP1-R agonists have been suggested for the use in patients with ischemic stroke (Maskery et al., 2021). In general, studies on the potential of GLP-1R agonists in stroke have focused on its effectiveness in either treating acute stroke or preventing the onset of stroke. In acute stroke, GLP-1R agonists have been suggested to treat stroke-induced hyperglycemia (post-stroke hyperglycemia) that is associated with, e.g., disruption of the blood-brain-barrier, intensified inflammatory reactions, edema, increased infarct size and worsening of functional outcomes (Li et al., 2013). Compared to insulin, GLP-1R agonists also have the advantage of preventing incidences of hypoglycemia. In a pilot study, 11 patients with ischemic stroke were treated with exenatide within app. 4-12 h after onset appeared to reduce hyperglycemia and hypoglycemic incidences (Daly et al., 2013). Another ongoing study (TEXAIS-study) also assesses the potential of exenatide in acute stroke (NCT03287076) (Muller et al., 2018). GLP-1R agonists have also shown effect in preventing stroke. Meta-analyses of large cardiovascular outcome trials have demonstrated that GLP-1R agonists, i.e., dulaglutide, liraglutide, injectable and oral semaglutide, have a potential stroke-protective effect (Pfeffer et al., 2015; Marso et al., 2016a,b; Holman et al., 2017; Hernandez et al., 2018; Kristensen et al., 2019; Alfayez et al., 2020; Gerstein et al., 2020; Strain et al., 2020). Another meta-analysis of large cardiovascular outcome trials such as SUSTAIN (injectable semaglutide), LEADER (liraglutide), HARMONY (albiglutide) (Hernandez et al., 2018), ELIXA (lixisenatide) (Pfeffer et al., 2015) and EXSCEL (exenatide) (Holman et al., 2017) appeared to reduce the risk of total stroke (by, i.e., 13% or 16%) (Bellastella et al., 2020; Gerstein et al., 2020). Semaglutide and dulaglutide were also associated with significantly reduced risks for stroke, where semaglutide appear to be better (Alfayez et al., 2020; Evans et al., 2021). However, in line with the potential neuroprotective effect of GLP-1R agonists in ischemic stroke, Rigshospitalet Denmark is running a randomized clinical trial of exenatide as an organ protecting agent, e.g., a brain-protecting agent, where stroke is one of the primary outcome measures (NCT02673931). Another Danish study is also investigating the effect of GLP-1R agonists on cerebral blood flow (NCT02829502). In fact, there are many other recruiting or completed studies investigating the protective effects of GLP-1R agonists (NCT02838589, NCT00418288, NCT00256256, NCT03948347) and also DPP4-inhibitors (NCT01107886, NCT00968708) in stroke. Thus, GLP-1R agonists show encouraging potential as stroke-protective agents, but there is still a need to investigate their effects in further clinical therapeutic trials.

Diabetic Neuropathy

Several preclinical studies have suggested that GLP-1 receptor activation is a promising mechanism that prevents neurodegeneration and improves neuroprotection in peripheral nerves (Yamamoto et al., 2002; Perry et al., 2007; Luciani et al., 2010; Griffioen et al., 2011; Himeno et al., 2011; Kan et al., 2012). A prospective, open-label pilot study of the DPP4-inhibitor teneligliptin in patients with T2D treatment has been shown to improve the patient’s peripheral and autonomic neuropathy status (Syngle et al., 2021). An unpublished clinical study has also associated a lacking responsiveness to GLP-1R agonist treatment (liraglutide and exenatide) with a higher presence of cardiovascular autonomic neuropathy (Clinical Trial Registration Number: 7459) (Duvnajak et al., 2017). However, DPP4-inhibitors, e.g., saxagliptin, have shown to have a neutral impact on the incidence of diabetic neuropathy (Taylor and Lam, 2020). A proof-of concept open-label randomized clinical trial has also assessed the effect of GLP-1R agonists on 46 patients with T2D and mild to moderate diabetic peripheral neuropathy (Jaiswal et al., 2015). Patients were randomized to be treated with either exenatide or insulin glargine for 18 months. The trial found no statistically significant effect on measures of neuropathy, i.e., no significant differences in confirmed clinical neuropathy, measures of cardiovascular autonomic neuropathy, nerve conduction tests nor intra-epidermal nerve fiber densities (Jaiswal et al., 2015). Although, the lack of significant differences in patients’ neuropathic statuses might be the result of: (1) the comparison to insulin, which also promotes glycemic control, and (2) that GLP-1 receptor agonists mainly prevent the development of neuropathy. The latter is also supported by the TODINELI-trial (Brock et al., 2019), where treatment of type 1 diabetic patients with liraglutide reduced levels of proinflammatory cytokines (IL-6) but did not improve the status of patients that had already established autonomic or diabetic polyneuropathy. Thus, clinical trials related to the neuroprotective role of GLP-1R agonists and DPP4-inhibitors in neuropathy are sparse (Mehta et al., 2021). Nevertheless, promising results from preclinical trials and the TODINELI-trial promote the idea of investigating the protective effects of GLP-1R agonists on neuropathy in further clinical trials.

Conclusion

The present review has summarized the current clinical evidence for a potential use of GLP-1R agonists in prospective neuroprotective treatment strategies against glaucoma and other neurodegenerative diseases. GLP-1R agonists have exerted a neuroprotective effect in several preclinical studies in both the brain and the retina. The most promising GLP-1R agonist in terms of efficacy, adverse effects, convenience for patients, cost-effectiveness and risk of cardiovascular complications is semaglutide, which is the only GLP-1R agonist that can be administrated as both an oral and injectable formulation. A recent association between exposure to GLP-1R agonists and a reduced risk of glaucoma makes it even more justified to consider the neuroprotective potential of GLP-1R agonists, particularly semaglutide, in anti-glaucomatous treatment strategies. Agents that increase GLP-1R signaling also appear to reduce the likelihood of developing diabetic retinopathy, AMD, cognitive dysfunction, motor dysfunction, stroke-induced neurodegenerative impairments, and neuropathy, supporting a potential neuroprotective effect of semaglutide in glaucoma. Furthermore, as oral semaglutide has recently entered phase III trials against Alzheimer’s disease, and injectable semaglutide is in the phase II trial of Parkinson’s disease as well as in the phase III trial against diabetic eye diseases, the potential of specifically semaglutide in glaucoma is additionally endorsed. However, there are currently no clinical nor any preclinical studies assessing the neuroprotective effects of semaglutide in glaucoma. Therefore, future studies are strongly needed to further investigate the potential of semaglutide as a repurposed novel neuroprotective agent in the treatment of glaucoma.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1

  AgostinoneJ.Alarcon-MartinezL.GamlinC.YuW. Q.WongR. O. L.Di PoloA. (2018). Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury.Brain1411963–1980. 10.1093/brain/awy142

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  AhmannA. J.CapehornM.CharpentierG.DottaF.HenkelE.LingvayI.et al (2018). Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, Randomized Clinical Trial.Diabetes Care41258–266. 10.2337/dc17-0417

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3

  AhrénB.MasmiquelL.KumarH.SarginM.KarsbølJ. D.JacobsenS. H.et al (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.Lancet Diabetes Endocrinol.5341–354. 10.1016/S2213-8587(17)30092-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  AielloL. P.Dcct/Edic Research Group. (2014). Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.Diabetes Care3717–23. 10.2337/dc13-2251

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  AlfayezO. M.AlmohammedO. A.AlkheziO. S.AlmutairiA. R.Al YamiM. S. (2020). Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.Cardiovasc. Diabetol.19:96. 10.1186/s12933-020-01070-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  Areosa SastreA.VernooijR. W.González-Colaço HarmandM.MartínezG. (2017). Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.Cochrane Database Syst Rev.6:CD003804. 10.1002/14651858.CD003804.pub2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  ArnoldS. E.ArvanitakisZ.Macauley-RambachS. L.KoenigA. M.WangH. Y.AhimaR. S.et al (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.Nat. Rev. Neurol.14168–181. 10.1038/nrneurol.2017.185

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  ArodaR. V.BauerR.HertzC. L.MontanyaE.SørrigR.WarrenM. L.et al (2020). Efficacy and safety of oral semaglutide by baseline age in the PIONEER clinical trial program.Poster Present. Am. Diabetes Assoc.44S24–S25. 10.2337/db20-932-P

  • CrossRef
  • Google Scholar

• 9

  ArodaV. R.BainS. C.CariouB.PiletičM.RoseL.AxelsenM.et al (2017). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.Lancet Diabetes Endocrinol.5355–366. 10.1016/S2213-8587(17)30085-2

  • CrossRef
  • Google Scholar

• 10

  ArodaV. R.RosenstockJ.TerauchiY.AltuntasY.LalicN. M.Morales VillegasE. C.et al (2019). PIONEER 1: randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.Diabetes Care.421724–1732. 10.2337/dc19-0749

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  AthaudaD.FoltynieT. (2016). Insulin resistance and Parkinson’s disease: a new target for disease modification?Prog. Neurobiol.1498–120. 10.1016/j.pneurobio.2016.10.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  AthaudaD.GulyaniS.KarnatiH. K.LiY.TweedieD.MustapicM.et al (2019a). Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: a Secondary Analysis of the Exenatide-PD Trial.JAMA Neurol.76420–429. 10.1001/jamaneurol.2018.4304

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  AthaudaD.MaclaganK.BudnikN.ZampedriL.HibbertS.SkeneS. S.et al (2018). What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: a Post Hoc Analysis.J. Parkinsons Dis.8247–258. 10.3233/JPD-181329

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  AthaudaD.MaclaganK.BudnikN.ZampedriL.HibbertS.Aviles-OlmosI.et al (2019b). Post hoc analysis of the Exenatide-PD trial-Factors that predict response.Eur. J. Neurosci.49410–421. 10.1111/ejn.14096

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  AthaudaD.MaclaganK.SkeneS. S.Bajwa-JosephM.LetchfordD.ChowdhuryK.et al (2017). Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial.Lancet3901664–1675. 10.1016/S0140-6736(17)31585-4

  • CrossRef
  • Google Scholar

• 16

  Aviles-OlmosI.DicksonJ.KefalopoulouZ.DjamshidianA.EllP.SoderlundT.et al (2013). Exenatide and the treatment of patients with Parkinson’s disease.J. Clin. Invest.1232730–2736. 10.1172/JCI68295

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  Aviles-OlmosI.DicksonJ.KefalopoulouZ.DjamshidianA.KahanJ.EllP.et al (2014). Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease.J. Parkinsons Dis.4337–344. 10.3233/JPD-140364

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18

  BainS. C.KlufasM. A.HoA.MatthewsD. R. (2019). Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review.Diabetes Obes. Metab.21454–466. 10.1111/dom.13538

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  BallardC.NørgaardC. H.FriedrichS.MørchL. S.GerdsT.MøllerD. V.et al (2020). Liraglutide and semaglutide: pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes.Alzheimers Dement.16:S9. 10.1002/alz.042909

  • CrossRef
  • Google Scholar

• 20

  BasalayM. V.DavidsonS. M.YellonD. M. (2019). Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.Cardiovasc. Drugs Ther.33661–667. 10.1007/s10557-019-06915-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  BellastellaG.MaiorinoM. I.LongoM.ScappaticcioL.ChiodiniP.EspositoK.et al (2020). Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.Stroke51666–669. 10.1161/STROKEAHA.119.027557

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  BethelM. A.DiazR.CastellanaN.BhattacharyaI.GersteinH. C.LakshmananM. C. (2021). HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: a Meta-analysis and Meta-regression.Diabetes Care44290–296. 10.2337/dc20-1815

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  BlitzerA. L.HamS. A.ColbyK. A.SkondraD. (2021). Association of Metformin Use With Age-Related Macular Degeneration: a Case-Control Study.JAMA Ophthalmol.139302–309. 10.1001/jamaophthalmol.2020.6331

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  BrauerR.WeiL.MaT.AthaudaD.GirgesC.VijiaratnamN.et al (2020). Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes.Brain1433067–3076. 10.1093/brain/awaa262

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25

  BrownE. E.BallJ. D.ChenZ.KhurshidG. S.ProsperiM.AshJ. D. (2019). The Common Antidiabetic Drug Metformin Reduces Odds of Developing Age-Related Macular Degeneration.Invest. Ophthalmol. Vis. Sci.601470–1477. 10.1167/iovs.18-26422

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26

  BrockC.HansenC. S.KarmisholtJ.MøllerH. J.JuhlA.FarmerA. D.et al (2019). Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.Br. J. Clin. Pharmacol.852512–2523. 10.1111/bcp.14063

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  CapehornM. S.CatarigA. M.FurbergJ. K.JanezA.PriceH. C.TadayonS.et al (2020). Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).Diabetes Metab.46100–109. 10.1016/j.diabet.2019.101117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  CedroneC.MancinoR.CerulliA.CesareoM.NucciC. (2008). Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects.Prog. Brain Res.1733–14. 10.1016/S0079-6123(08)01101-1

  • CrossRef
  • Google Scholar

• 29

  ChangY. F.ZhangD.HuW. M.LiuD. X.LiL. (2020). Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apoptosis.J. Clin. Neurosci.81234–239. 10.1016/j.jocn.2020.09.054

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  ChenY. Y.ShenY. C.LaiY. J.WangC. Y.LinK. H.FengS. C.et al (2019). Association between Metformin and a Lower Risk of Age-Related Macular Degeneration in Patients with Type 2 Diabetes.J. Ophthalmol.2019:1649156. 10.1155/2019/1649156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  ChopraV.VarmaR.FrancisB. A.WuJ.TorresM.AzenS. P.et al (2008). Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study.Ophthalmology115227–232.e1. 10.1016/j.ophtha.2007.04.049

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  ChungY. R.HaK. H.KimH. C.ParkS. J.LeeK.KimD. J. (2019). Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: a Real World-Based Cohort Study.Diabetes Metab. J.43640–648. 10.4093/dmj.2018.0137

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  ChungY. R.ParkS. W.KimJ. W.KimJ. H.LeeK. (2016). Protective effects of dipeptidyl peptidase-4 inhibitors on progression of diabetic retinopathy in patients with type 2 diabetes.Retina362357–2363. 10.1097/IAE.0000000000001098

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  ClaxtonA.BakerL. D.HansonA.TrittschuhE. H.CholertonB.MorganA.et al (2015). Long Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer’s Disease Dementia.J. Alzheimers. Dis.451269–1270. 10.3233/JAD-159002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35

  CourrègesJ. P.VilsbøllT.ZdravkovicM.Le-ThiT.KrarupT.SchmitzO.et al (2008). Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.Diabetes Med.251129–1131. 10.1111/j.1464-5491.2008.02484.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36

  CraftS.AsthanaS.CookD. G.BakerL. D.CherrierM.PurgananK.et al (2003). Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype.Psychoneuroendocrinology28809–822. 10.1016/s0306-4530(02)00087-2

  • CrossRef
  • Google Scholar

• 37

  CraftS.AsthanaS.NewcomerJ. W.WilkinsonC. W.MatosI. T.BakerL. D.et al (1999). Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose.Arch. Gen. Psychiatry.561135–1140. 10.1001/archpsyc.56.12.1135

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38

  CraftS.BakerL. D.MontineT. J.MinoshimaS.WatsonG. S.ClaxtonA.et al (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.Arch. Neurol.6929–38. 10.1001/archneurol.2011.233

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  CraftS.ClaxtonA.BakerL. D.HansonA. J.CholertonB.TrittschuhE. H.et al (2017). Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial.J. Alzheimers. Dis.571325–1334. 10.3233/JAD-161256

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40

  CraftS.NewcomerJ.KanneS.Dagogo-JackS.CryerP.ShelineY.et al (1996). Memory improvement following induced hyperinsulinemia in Alzheimer’s disease.Neurobiol. Aging7123–130. 10.1016/0197-4580(95)02002-0

  • CrossRef
  • Google Scholar

• 41

  Cukierman-YaffeT.GersteinH. C.ColhounH. M.DiazR.García-PérezL. E.LakshmananM.et al (2020). Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.Lancet Neurol.19582–590. 10.1016/S1474-4422(20)30173-3

  • CrossRef
  • Google Scholar

• 42

  DadaT. (2017). Is Glaucoma a Neurodegeneration caused by Central Insulin Resistance: diabetes Type 4?J. Curr. Glaucoma Pract.1177–79. 10.5005/jp-journals-10028-1228

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43

  DalyS. C.ChemmanamT.LohP. S.GilliganA.DearA. E.SimpsonR. W.et al (2013). Exenatide in acute ischemic stroke.Int. J. Stroke8E44. 10.1111/ijs.12073

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  DaviesM.PieberT. R.Hartoft-NielsenM. L.HansenO.JabbourS.RosenstockJ. (2017). Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: a Randomized Clinical Trial.JAMA3181460–1470. 10.1001/jama.2017.14752

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45

  de VoogdS.IkramM. K.WolfsR. C.JansoniusN. M.HofmanA.de JongP. T. (2005). Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study.Ophthalmology1121487–1493. 10.1016/j.ophtha.2005.04.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46

  Diabetes Control and Complications Trial Research GroupNathanD. M.GenuthS.LachinJ.ClearyP.CroffordO.et al (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N. Engl. J. Med.329977–986. 10.1056/NEJM199309303291401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  DielemansI.VingerlingJ. R.WolfsR. C.HofmanA.GrobbeeD. E.de JongP. T. (1994). The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study.Ophthalmology1011851–1855. 10.1016/s0161-6420(94)31090-6

  • CrossRef
  • Google Scholar

• 48

  DourosA.FilionK. B.YinH.YuO. H.EtminanM.UdellJ. A.et al (2018). Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.Diabetes Care412330–2338. 10.2337/dc17-2280

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  DruckerD. J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.Cell. Metab.27740–756. 10.1016/j.cmet.2018.03.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50

  DuvnajakI.BulumT.RebrinaS. V. (2017). Autonomic Neuropathy is Associated with the Lack of Glucagon-like Peptide-1 Receptor Agonists Treatment Efficacy in Patients with Type 2 Diabetes. Available online at: https://www.easd.org/virtualmeeting/home.html#!resources/autonomic-neuropathy-is-associated-with-the-lack-of-glucagon-like-peptide-1-receptor-agonists-treatment-efficacy-in-patients-with-type-2-diabetes(accessed August 10, 2021).

  • Google Scholar

• 51

  Ece Bayram, and Irene Litvan. (2020). Lowering the risk of Parkinson’s disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.Brain1432868–2871. 10.1093/brain/awaa287

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52

  EllisJ. D.EvansJ. M.RutaD. A.BainesP. S.LeeseG.MacDonaldT. M.et al (2000). Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit.Br. J. Ophthalmol.841218–1224. 10.1136/bjo.84.11.1218

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  Evaluate (2020). CTAD 2020 – ELAD fails, but GLP-1s could still have a future in Alzheimer’s. Available online at: https://www.evaluate.com/vantage/articles/news/snippets/ctad-2020-elad-fails-glp-1s-could-still-have-future-alzheimers(accessed March 31, 2021).

  • Google Scholar

• 54

  EvansL. M.MellbinL.JohansenP.LawsonJ.PaineA.SandbergA. (2021). A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.Endocrinol. Diabetes Metab.4:e00259. 10.1002/edm2.259

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  FaiqM. A.DadaT. (2017). Diabetes Type 4: a Paradigm Shift in the Understanding of Glaucoma, the Brain Specific Diabetes and the Candidature of Insulin as a Therapeutic Agent.Curr. Mol. Med.1746–59. 10.2174/1566524017666170206153415

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  FaiqM. A.DadaR.SalujaD.DadaT. (2014). Glaucoma–diabetes of the brain: a radical hypothesis about its nature and pathogenesis.Med. Hypotheses82535–546. 10.1016/j.mehy.2014.02.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  FanY. P.WuC. T.LinJ. L.HsiungC. A.LiuH. Y.LaiJ. N.et al (2020). Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: a Population-Based Cohort Study.J. Diabetes Res.2020:9161039. 10.1155/2020/9161039

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  FanY.LiuK.WangQ.RuanY.ZhangY.YeW. (2014). Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis.Mol. Vis.20141557–1568.

  • Pubmed Abstract
  • Google Scholar

• 59

  FemminellaG. D.FrangouE.LoveS. B.BuszaG.HolmesC.RitchieC.et al (2019). Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study).Trials20:191. 10.1186/s13063-019-3259-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  FemminellaG. D.LivingstonN. R.RazaS.van der DoefT.FrangouE.LoveS.et al (2021). Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?Alzheimers. Res. Ther.13:47. 10.1186/s13195-021-00784-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  FilippatosT. D.PanagiotopoulouT. V.ElisafM. S. (2014). Adverse Effects of GLP-1 Receptor Agonists.Rev. Diabet. Stud.11202–230. 10.1900/RDS.2014.11.202

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62

  FioryF.PerruoloG.CimminoI.CabaroS.PignalosaF. C.MieleC.et al (2019). The Relevance of Insulin Action in the Dopaminergic System.Front. Neurosci.2019:868. 10.3389/fnins.2019.00868

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  GaboritB.JullaJ. B.BesbesS.ProustM.VincentelliC.AlosB.et al (2020). Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.J. Clin. Endocrinol. Metab.105:dgz069. 10.1210/clinem/dgz069

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  GejlM.GjeddeA.EgefjordL.MøllerA.HansenS. B.VangK.et al (2016). In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: randomized, Placebo-Controlled, Double-Blind Clinical Trial.Front. Aging Neurosci.8:108. 10.3389/fnagi.2016.00108

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  GersteinH. C.HartR.ColhounH. M.DiazR.LakshmananM.BotrosF. T.et al (2020). The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.Lancet Diabetes Endocrinol.8106–114. 10.1016/S2213-8587(19)30423-1

  • CrossRef
  • Google Scholar

• 66

  GonçalvesA.LinC. M.MuthusamyA.Fontes-RibeiroC.AmbrósioA. F.AbcouwerS. F.et al (2016). Protective Effect of a GLP-1 Analog on Ischemia-Reperfusion Induced Blood-Retinal Barrier Breakdown and Inflammation.Invest. Ophthalmol. Vis. Sci.572584–92. 10.1167/iovs.15-19006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  GreenJ. B.BethelM. A.ArmstrongP. W.BuseJ. B.EngelS. S.GargJ.et al (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.N. Engl. J. Med.373232–242. 10.1056/NEJMoa1501352

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68

  GriffioenK. J.WanR.OkunE.WangX.Lovett-BarrM. R.LiY.et al (2011). GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.Cardiovasc. Res.8972–78. 10.1093/cvr/cvq271

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  GutniakM.OrskovC.HolstJ. J.AhrénB.EfendicS. (1992). Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.N. Engl. J. Med.3261316–1322. 10.1056/NEJM199205143262003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  HallschmidM. (2021). Intranasal Insulin for Alzheimer’s Disease.CNS Drugs3521–37. 10.1007/s40263-020-00781-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  HansenB. B.NuhohoS.AliS. N.Dang-TanT.ValentineW. J.MalkinS. J. P.et al (2020). Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.J. Med. Econ.23650–658. 10.1080/13696998.2020.1722678

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  HanyudaA.SawadaN.YukiK.UchinoM.OzawaY.SasakiM.et al (2020). Relationships of diabetes and hyperglycaemia with intraocular pressure in a Japanese population: the JPHC-NEXT Eye Study.Sci. Rep.10:5355. 10.1038/s41598-020-62135-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73

  HaoM.KuangH. Y.FuZ.GaoX. Y.LiuY.DengW. (2012). Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanism.Neurochem. Int.611–6. 10.1016/j.neuint.2012.04.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74

  HeijlA.LeskeM. C.BengtssonB.HymanL.BengtssonB.HusseinM. (2002). Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.Arch. Ophthalmol.1201268–1279. 10.1001/archopht.120.10.1268

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  HelkalaE. L.NiskanenL.ViinamakiH.PartanenJ.UusitupaM. (1995). Short-term and long-term memory in elderly patients with NIDDM.Diabet. Care18681–685. 10.2337/diacare.18.5.681

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  HernandezA. F.GreenJ. B.JanmohamedS.D’AgostinoR. B.Sr.GrangerC. B.JonesN. P.et al (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.Lancet3921519–1529. 10.1016/S0140-6736(18)32261-X

  • CrossRef
  • Google Scholar

• 77

  HimenoT.KamiyaH.NaruseK.HaradaN.OzakiN.SeinoY.et al (2011). Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.Diabetes602397–2406. 10.2337/db10-1462

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  HoC. H.WongJ. K. W. (2019). Role of 24-Hour Intraocular Pressure Monitoring in Glaucoma Management.J. Ophthalmol.2019:3632197. 10.1155/2019/3632197

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  HolmanR. R.BethelM. A.MentzR. J.ThompsonV. P.LokhnyginaY.BuseJ. B.et al (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.N. Engl. J. Med.3771228–1239. 10.1056/NEJMoa1612917

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  HölscherC. (2019). Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease.Front. Aging Neurosci.11:88. 10.3389/fnagi.2019.00088

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  HorwitzA.PetrovskiB. ÉTorp-PedersenC.KolkoM. (2016). Danish Nationwide Data Reveal a Link between Diabetes Mellitus. Diabetic Retinopathy, and Glaucoma.J. Diabetes Res.2016:2684674. 10.1155/2016/2684674

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  HusainM.BirkenfeldA. L.DonsmarkM.DunganK.EliaschewitzF. G.FrancoD. R.et al (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N. Engl. J. Med.381841–851. 10.1056/NEJMoa1901118

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  IshiiH.HansenB. B.LangerJ.HorioH. (2021). Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: the PIONEER 10 Randomized. Active-Controlled Trial.Diabetes Ther.12613–623. 10.1007/s13300-020-00985-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  IsikA. T.SoysalP.YayA.UsarelC. (2017). The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease.Diabetes Res. Clin. Pract.123192–198. 10.1016/j.diabres.2016.12.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  IwaseA.SuzukiY.AraieM.YamamotoT.AbeH.ShiratoS.et al (2004). The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study.Ophthalmology1111641–1648. 10.1016/j.ophtha.2004.03.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  JaiswalM.MartinC. L.BrownM. B.CallaghanB.AlbersJ. W.FeldmanE. L.et al (2015). Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.J. Diabetes Compl.291287–1294. 10.1016/j.jdiacomp.2015.07.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  JansonJ.LaedtkeT.ParisiJ. E.O’BrienP.PetersenR. C.ButlerP. C. (2004). Increased risk of type 2 diabetes in Alzheimer disease.Diabetes53474–481.

  • Google Scholar

• 88

  JiL.DongX.LiY.LiY.LimS.LiuM.et al (2020). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial.Diabetes Obes. Metab.23404–414. 10.1111/dom.14232

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  JingiA. M.TankeuA. T.AtebaN. A.NoubiapJ. J. (2017). Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis.BMC Endocr. Disord.17:63. 10.1186/s12902-017-0213-3

  • CrossRef
  • Google Scholar

• 90

  JinnouchiH.SugiyamaS.YoshidaA.HieshimaK.KurinamiN.SuzukiT.et al (2015). Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.J. Diabetes Res.2015:706416. 10.1155/2015/706416

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  JonassonF.DamjiK. F.ArnarssonA.SverrissonT.WangL.SasakiH.et al (2003). Prevalence of open-angle glaucoma in Iceland: reykjavik Eye Study.Eye17747–753. 10.1038/sj.eye.6700374

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  JungY.HanK.ParkH. L.ParkC. K. (2018). Type 2 diabetes mellitus and risk of open-angle glaucoma development in Koreans: an 11-year nationwide propensity-score-matched study.Diabetes Metab.44328–332. 10.1016/j.diabet.2017.09.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  KakuK.YamadaY.WatadaH.AbikoA.NishidaT.ZachoJ.et al (2018). Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial.Diabetes Obes. Metab.201202–1212. 10.1111/dom.13218

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  KaloudaP.KeskiniC.AnastasopoulosE.TopouzisF. (2017). Achievements and Limits of Current Medical Therapy of Glaucoma.Dev. Ophthalmol.591–14. 10.1159/000458482

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  KanM.GuoG.SinghB.SinghV.ZochodneD. W. (2012). Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.J. Neuropathol. Exp. Neurol.71494–510. 10.1097/NEN.0b013e3182580673

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  KastinA. J.AkerstromV.PanW. (2002). Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.J. Mol. Neurosci.187–14. 10.1385/JMN:18:1-2:07

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  KellarD.CraftS. (2020). Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches.Lancet Neurol.19758–766. 10.1016/S1474-4422(20)30231-3

  • CrossRef
  • Google Scholar

• 98

  KernW.PetersA.Fruehwald-SchultesB.DeiningerE.BornJ.FehmH. L. (2001). Improving influence of insulin on cognitive functions in humans.Neuroendocrinology74270–280. 10.1159/000054694

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  KhooT. K.LinJ. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.N. Engl. J. Med.385:e4. 10.1056/NEJMc2106918

  • CrossRef
  • Google Scholar

• 100

  KimN. H.ChoiJ.KimN. H.ChoiK. M.BaikS. H.LeeJ.et al (2018). Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: a population-based study.Diabetes Metab.44361–367. 10.1016/j.diabet.2018.03.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  KleinB. E.KleinR.SponselW. E.FrankeT.CantorL. B.MartoneJ.et al (1992). Prevalence of glaucoma. The Beaver Dam Eye Study.Ophthalmology991499–1504. 10.1016/s0161-6420(92)31774-9

  • CrossRef
  • Google Scholar

• 102

  KolkoM. (2015). Present and New Treatment Strategies in the Management of Glaucoma.Open Ophthalmol. J.989–100. 10.2174/1874364101509010089

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  KolkoM. (2017). [Detection and prevention of blindness in patients with glaucoma is a socio-economical challenge].Ugeskr Laeg.179:V06160444.

  • Pubmed Abstract
  • Google Scholar

• 104

  KolkoM.HorwitzA.ThygesenJ.JeppesenJ.Torp-PedersenC. (2015). The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: a Nationwide Study.PLoS One10:e0132048. 10.1371/journal.pone.0132048

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  KristensenS. L.RørthR.JhundP. S.DochertyK. F.SattarN.PreissD.et al (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol.7776–785. 10.1016/S2213-8587(19)30249-9

  • CrossRef
  • Google Scholar

• 106

  LauJ.BlochP.SchäfferL.PetterssonI.SpetzlerJ.KofoedJ.et al (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.J. Med. Chem.587370–7380. 10.1021/acs.jmedchem.5b00726

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  LeeW. J.JeoungJ. W.NaK. I.KimY. K.KimC. Y.ParkK. H. (2018). Relationship Between Open-angle Glaucoma and Stroke: a 2010 to 2012 Korea National Health and Nutrition Examination Survey.J. Glaucoma.2722–27. 10.1097/IJG.0000000000000829

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  LeskeM. C.ConnellA. M.SchachatA. P.HymanL. (1994). The Barbados Eye Study. Prevalence of open angle glaucoma.Arch. Ophthalmol.112821–829. 10.1001/archopht.1994.01090180121046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  LiW. A.Moore-LangstonS.ChakrabortyT.RafolsJ. A.ContiA. C.DingY. (2013). Hyperglycemia in stroke and possible treatments.Neurol. Res.35479–491. 10.1179/1743132813Y.0000000209

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  LiY.RyuC.MunieM.NoorullaS.RanaS.EdwardsP.et al (2018). Association of Metformin Treatment with Reduced Severity of Diabetic Retinopathy in Type 2 Diabetic Patients.J. Diabetes Res.2018:2801450. 10.1155/2018/2801450

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  LimS. W.van WijngaardenP.HarperC. A.Al-QureshiS. H. (2019). Early worsening of diabetic retinopathy due to intensive glycaemic control.Clin. Exp. Ophthalmol.47265–273. 10.1111/ceo.13393

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  LinH. C.SteinJ. D.NanB.ChildersD.Newman-CaseyP. A.ThompsonD. A.et al (2015). Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus.JAMA Ophthalmol.133915–923. 10.1001/jamaophthalmol.2015.1440

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  LinT. C.HwangD. K.HsuC. C.PengC. H.WangM. L.ChiouS. H.et al (2017). Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study.PLoS One12:e0188136. 10.1371/journal.pone.0188136

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  LingvayI.CatarigA. M.FriasJ. P.KumarH.LausvigN. L.le RouxC. W.et al (2019). Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.Lancet Diabetes Endocrinol.7834–844. 10.1016/S2213-8587(19)30311-0

  • CrossRef
  • Google Scholar

• 115

  LucianiP.DeleddaC.BenvenutiS.CellaiI.SqueccoR.MoniciM.et al (2010). Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model.Cell. Mol. Life Sci.673711–3723. 10.1007/s00018-010-0398-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  MaleškićS.KusturicaJ.GušićE.Rakanović-TodićM.ŠečićD.Burnazović-RistićL.et al (2017). Metformin use associated with protective effects for ocular complications in patients with type 2 diabetes - observational study.Acta Med. Acad.46116–123. 10.5644/ama2006-124.196

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  MansurR. B.AhmedJ.ChaD. S.WoldeyohannesH. O.SubramaniapillaiM.LovshinJ.et al (2017). Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study.J. Affect. Disord.2017114–120. 10.1016/j.jad.2016.09.056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  MarsoS. P.BainS. C.ConsoliA.EliaschewitzF. G.JódarE.LeiterL. A.et al (2016a). SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N. Engl. J. Med.3751834–1844. 10.1056/NEJMoa1607141

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  MarsoS. P.DanielsG. H.Brown-FrandsenK.KristensenP.MannJ. F.NauckM. A.et al (2016b). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.N. Engl. J. Med.375311–322. 10.1056/NEJMoa1603827

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  MaskeryM. P.HolscherC.JonesS. P.PriceC. I.StrainW. D.WatkinsC. L.et al (2021). Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review.J. Cereb. Blood Flow Metab.4114–30. 10.1177/0271678X20952011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  McCleanP. L.ParthsarathyV.FaivreE.HölscherC. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease.J. Neurosci.316587–6594. 10.1523/JNEUROSCI.0529-11.2011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  MehtaK.BehlT.KumarA.UddinM. S.ZenginG.AroraS. (2021). Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: current Perspective and Future Directions.Curr. Protein Pept. Sci.224–18. 10.2174/1389203721999201208195901

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  MosenzonO.BlicherT. M.RosenlundS.ErikssonJ. W.HellerS.HelsO. H.et al (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.Lancet Diabetes Endocrinol.7515–527. 10.1016/S2213-8587(19)30192-5

  • CrossRef
  • Google Scholar

• 124

  MousaS. A.AyoubB. M. (2019). Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.Neural. Regen. Res.14745–748. 10.4103/1673-5374.249217

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125

  MullerC.CheungN. W.DeweyH.ChurilovL.MiddletonS.ThijsV.et al (2018). Treatment with exenatide in acute ischemic stroke trial protocol: a prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia.Int. J. Stroke13857–862. 10.1177/1747493018784436

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  MullinsR. J.MustapicM.ChiaC. W.CarlsonO.GulyaniS.TranJ.et al (2019). A Pilot Study of Exenatide Actions in Alzheimer’s Disease.Curr. Alzheimer. Res.16741–752. 10.2174/1567205016666190913155950

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  NaK. S.KimJ. H.PaikJ. S.ChoW. K.HaM.ParkY. G.et al (2020). Underweight increases the risk of primary open-angle glaucoma in diabetes patients: a Korean nationwide cohort study.Medicine99:e19285. 10.1097/MD.0000000000019285

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  NauckM. A.PetrieJ. R.SestiG.MannucciE.CourrègesJ. P.LindegaardM. L.et al (2016). A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.Diabetes Care39231–241. 10.2337/dc15-0165

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  NethB. J.CraftS. (2017). Insulin resistance and Alzheimer’s disease: bioenergetic linkages.Front. Aging Neurosci.9:345. 10.3389/fnagi.2017.00345

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  NewtonJ. L. (2005). Effect of age-related changes in gastric physiology on tolerability of medications for older people.Drugs Aging22655–661. 10.2165/00002512-200522080-00003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131

  No authors listed. (1998). Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.Arch. Ophthalmol.116874–886. 10.1001/archopht.116.7.874

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  No authors listed. (1999). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet352837–853. 10.1016/s0140-6736(98)07019-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  O’BrienJ. T.ErkinjunttiT.ReisbergB.RomanG.SawadaT.PantoniL.et al (2003). Vascular cognitive impairment.Lancet Neurol.289–98. 10.1016/s1474-4422(03)00305-3

  • CrossRef
  • Google Scholar

• 134

  OngL. K.WalkerF. R.NilssonM. (2017). Is Stroke a Neurodegenerative Condition? A Critical Review of Secondary Neurodegeneration and Amyloid-beta Accumulation after Stroke.AIMS Med. Sci.41–16. 10.3934/medsci.2017.1.1

  • CrossRef
  • Google Scholar

• 135

  OshitariT.FujimotoN.HanawaK.Adachi-UsamiE.RoyS. (2007). Effect of chronic hyperglycemia on intraocular pressure in patients with diabetes.Am. J. Ophthalmol.143363–365. 10.1016/j.ajo.2006.09.033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  OttC.RaffU.SchmidtS.KistnerI.FriedrichS.BramlageP.et al (2014). Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes.Cardiovasc. Diabetol.13:19. 10.1186/1475-2840-13-19

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  PatelV. J.JoharapurkarA. A.ShahG. B.JainM. R. (2014). Effect of GLP-1 based therapies on diabetic dyslipidemia.Curr. Diabetes Rev.10238–250. 10.2174/1573399810666140707092506

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138

  PerlmuterL. C.HakamiM. K.Hodgson-HarringtonC.GinsbergJ.KatzJ.SingerD. E.et al (1984). Decreased cognitive function in aging non-insulin-dependent diabetic patients.Am. J. Med.771043–1048. 10.1016/0002-9343(84)90186-4

  • CrossRef
  • Google Scholar

• 139

  PerryT.HollowayH. W.WeerasuriyaA.MoutonP. R.DuffyK.MattisonJ. A.et al (2007). Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.Exp. Neurol.203293–301. 10.1016/j.expneurol.2006.09.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140

  PetersD.BengtssonB.HeijlA. (2013). Lifetime risk of blindness in open-angle glaucoma.Am. J. Ophthalmol.156724–730. 10.1016/j.ajo.2013.05.027

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  PfefferM. A.ClaggettB.DiazR.DicksteinK.GersteinH. C.KøberL. V.et al (2015). Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.N. Engl. J. Med.3732247–2257. 10.1056/NEJMoa1509225

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  PieberT. R.BodeB.MertensA.ChoY. M.ChristiansenE.HertzC. L.et al (2019). Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.Lancet Diabetes Endocrinol.7528–539. 10.1016/S2213-8587(19)30194-9

  • CrossRef
  • Google Scholar

• 143

  PratleyR. E.ArodaV. R.LingvayI.LüdemannJ.AndreassenC.NavarriaA.et al (2018). SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.Lancet Diabetes Endocrinol.6275–286. 10.1016/S2213-8587(18)30024-X

  • CrossRef
  • Google Scholar

• 144

  PratleyR.AmodA.HoffS. T.KadowakiT.LingvayI.NauckM.et al (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.Lancet39439–50. 10.1016/S0140-6736(19)31271-1

  • CrossRef
  • Google Scholar

• 145

  QuigleyH. A. (2009). Can diabetes be good for glaucoma? Why can’t we believe our own eyes (or data)?Arch. Ophthalmol.127227–229. 10.1001/archophthalmol.2008.596

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  QuigleyH. A. (2019). 21st century glaucoma care.Eye33254–260. 10.1038/s41433-018-0227-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  RamosH.BogdanovP.SampedroJ.HuertaJ.SimóR.HernándezC. (2020). Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: involvement of Oxidative Stress.Antioxidants9:846. 10.3390/antiox9090846

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148

  RegerM. A.WatsonG. S.FreyW. H.IICholertonB.KeelingM. L.BelongiaD. A.et al (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.Neurobiol. Aging.27451–458. 10.1016/j.neurobiolaging.2005.03.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  RegerM. A.WatsonG. S.GreenP. S.BakerL. D.CholertonB.FishelM. A.et al (2008a). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.J. Alzheimers. Dis.13323–331. 10.3233/jad-2008-13309

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  RegerM. A.WatsonG. S.GreenP. S.WilkinsonC. W.BakerL. D.CholertonB.et al (2008b). Intranasal insulin improves cognition and modulates beta-amyloid in early AD.Neurology70440–448. 10.1212/01.WNL.0000265401.62434.36

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  RenX.SunL.WeiL.LiuJ.ZhuJ.YuQ.et al (2020). Liraglutide Up-regulation Thioredoxin Attenuated Müller Cells Apoptosis in High Glucose by Regulating Oxidative Stress and Endoplasmic Reticulum Stress.Curr. Eye Res.451283–1291. 10.1080/02713683.2020.1737137

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152

  RimT. H.LeeS. Y.BaeH. W.KimS. S.KimC. Y. (2018). Increased stroke risk among patients with open-angle glaucoma: a 10-year follow-up cohort study.Br. J. Ophthalmol.102338–343. 10.1136/bjophthalmol-2017-310415

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153

  RizviA. A.PattiA. M.GiglioR. V.NikolicD.AmatoA.Al-BusaidiN.et al (2015). Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.Expert Opin. Biol. Ther.151391–1397. 10.1517/14712598.2015.1067299

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  RizzoM.AbateN.ChandaliaM.RizviA. A.GiglioR. V.NikolicD.et al (2015). Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.J. Clin. Endocrinol. Metab.100603–606. 10.1210/jc.2014-2291

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155

  RizzoM.RizviA. A.PattiA. M.NikolicD.GiglioR. V.CastellinoG.et al (2016). Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.Cardiovasc. Diabetol.15:162. 10.1186/s12933-016-0480-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  RodbardH. W.LingvayI.ReedJ.de la RosaR.RoseL.SugimotoD.et al (2018). Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): a Randomized, Controlled Trial.J. Clin. Endocrinol. Metab.1032291–2301. 10.1210/jc.2018-00070

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157

  RodbardH. W.RosenstockJ.CananiL. H.DeerochanawongC.GumprechtJ.LindbergS. Øet al (2019). Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: the PIONEER 2 Trial.Diabetes Care422272–2281. 10.2337/dc19-0883

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  RosenstockJ.AllisonD.BirkenfeldA. L.BlicherT. M.DeenadayalanS.JacobsenJ. B.et al (2019). Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: the PIONEER 3 Randomized Clinical Trial.JAMA3211466–1480. 10.1001/jama.2019.2942

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159

  SandovalD.SisleyS. R. (2015). Brain GLP-1 and insulin sensitivity.Mol. Cell. Endocrinol.201527–32. 10.1016/j.mce.2015.02.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  SchrijversE. M.WittemanJ. C.SijbrandsE. J.HofmanA.KoudstaalP. J.BretelerM. M. (2010). Insulin metabolism and the risk of Alzheimer disease: the Rotterdam study.Neurology751982–1987. 10.1212/WNL.0b013e3181ffe4f6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  SecherA.JelsingJ.BaqueroA. F.Hecksher-SørensenJ.CowleyM. A.DalbøgeL. S.et al (2014). The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.J. Clin. Invest.1244473–4488. 10.1172/JCI75276

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  SeiduS.MellbinL.KaiserM.KhuntiK. (2021). Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?Prim. Care Diabetes1559–68. 10.1016/j.pcd.2020.07.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163

  SeinoY.TerauchiY.OsonoiT.YabeD.AbeN.NishidaT.et al (2018). Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.Diabetes Obes. Metab.20378–388. 10.1111/dom.13082

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  SorliC.HarashimaS. I.TsoukasG. M.UngerJ.KarsbølJ. D.HansenT.et al (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.Lancet Diabetes Endocrinol.5251–260. 10.1016/S2213-8587(17)30013-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165

  SterlingJ. K.AdetunjiM. O.GutthaS.BargoudA. R.UyhaziK. E.RossA. G.et al (2020). GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension.Cell Rep.33:108271. 10.1016/j.celrep.2020.108271

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  SterlingJ.HuaP.DunaiefJ. L.CuiQ. N.VanderBeekB. L. (2021). Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma [published online ahead of print, 2021 Aug 19].Br. J. Ophthalmol. Bjophthalmol.2021:319232. 10.1136/bjophthalmol-2021-319232

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167

  StrainW. D.HolstA. G.RasmussenS.SaevereidH. A.JamesM. A. (2020). Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials.Euro. Heart J.41:ehaa946.2424.

  • Google Scholar

• 168

  SvenningssonP.WirdefeldtK.YinL.FangF.MarkakiI.EfendicS.et al (2016). Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.Mov. Disord.311422–1423. 10.1002/mds.26734

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  SyngleA.ChahalS.VohraK. (2021). Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.Neurol. Sci.421429–1436. 10.1007/s10072-020-04681-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  TangH.LiG.ZhaoY.WangF.GowerE. W.ShiL.et al (2018). Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis.Diabetes Obes. Metab.201262–1279. 10.1111/dom.13232

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  TaylorO. M.LamC. (2020). The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: a Systematic Review.Curr. Ther. Res. Clin. Exp.93:100596. 10.1016/j.curtheres.2020.100596

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  ThamY.-C.LiX.WongT. Y.QuigleyH. A.AungT.ChengC.-Y. (2014). Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.Ophthalmology1212081–2090. 10.1016/j.ophtha.2014.05.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  The U.S. Food and Drug administration (2019). FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes. Available online at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes(accessed March 31, 2021).

  • Google Scholar

• 174

  TielschJ. M.KatzJ.QuigleyH. A.JavittJ. C.SommerA. (1995). Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey.Ophthalmology10248–53. 10.1016/s0161-6420(95)31055-x

  • CrossRef
  • Google Scholar

• 175

  TopouzisF.AnastasopoulosE. (2007). Glaucoma—The Importance of Early Detection and Early Treatment.Eur. Ophthalmic. Rev.1313–14. 10.17925/EOR.2007.00.00.13

  • CrossRef
  • Google Scholar

• 176

  TrujilloJ. M.NufferW.SmithB. A. (2021). GLP-1 receptor agonists: an updated review of head-to-head clinical studies.Ther. Adv. Endocrinol. Metab.12:2042018821997320. 10.1177/2042018821997320

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  UzoigweC.LiangY.WhitmireS.PaprockiY. (2021). Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.Diabetes Ther.121475–1489. 10.1007/s13300-021-01053-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  VanhanenM.KuusistoJ.KoivistoK.MykkänenL.HelkalaE. L.HänninenT.et al (1999). Type-2 diabetes and cognitive function in a non-demented population.Acta Neurol. Scand.10097–101. 10.1111/j.1600-0404.1999.tb01045.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  VilsbøllT.BainS. C.LeiterL. A.LingvayI.MatthewsD.SimóR.et al (2018). Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.Diabetes Obes. Metab.20889–897. 10.1111/dom.13172

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  WangT.HongJ. L.GowerE. W.PateV.GargS.BuseJ. B.et al (2018). Incretin-Based Therapies and Diabetic Retinopathy: real-World Evidence in Older U.S. Adults.Diabetes Care.411998–2009. 10.2337/dc17-2285

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  WarrenM.ChaykinL.TrachtenbargD.NayakG.WijayasingheN.CariouB. (2018). Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials.Diabetes Obes. Metab.202291–2297. 10.1111/dom.13331

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  WatsonK. T.WroolieT. E.TongG.Foland-RossL. C.FrangouS.SinghM.et al (2019). Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease.Behav. Brain Res.356271–278. 10.1016/j.bbr.2018.08.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  WelinderL. G.RiisA. H.KnudsenL. L.ThomsenR. W. (2009). Diabetes, glycemic control and risk of medical glaucoma treatment: a population-based case-control study.Clin. Epidemiol.1, 125–31. 10.2147/clep.s6831

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  WensorM. D.McCartyC. A.StanislavskyY. L.LivingstonP. M.TaylorH. R. (1998). The prevalence of glaucoma in the Melbourne Visual Impairment Project.Ophthalmology105733–739. 10.1016/S0161-6420(98)94031-3

  • CrossRef
  • Google Scholar

• 185

  WrightE. E.Jr.ArodaV. R. (2020). Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.Postgrad. Med.13226–36. 10.1080/00325481.2020.1798127

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  XueJ.WangC.PanC.XingH.XuL.ChenX.et al (2020). Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI.Exp Ther Med.191356–1362. 10.3892/etm.2019.8339

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  YabeD.NakamuraJ.KanetoH.DeenadayalanS.NavarriaA.GislumM.et al (2020). Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.Lancet Diabetes Endocrinol.8392–406. 10.1016/S2213-8587(20)30074-7

  • CrossRef
  • Google Scholar

• 188

  YamadaY.KatagiriH.HamamotoY.DeenadayalanS.NavarriaA.NishijimaK.et al (2020). Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.Lancet Diabetes Endocrinol.8377–391. 10.1016/S2213-8587(20)30075-9

  • CrossRef
  • Google Scholar

• 189

  YamamotoH.LeeC. E.MarcusJ. N.WilliamsT. D.OvertonJ. M.LopezM. E.et al (2002). Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.J. Clin. Invest.11043–52. 10.1172/JCI15595

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  YangX.FengP.ZhangX.LiD.WangR.JiC.et al (2019). The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke.Neuropharmacology158:107748. 10.1016/j.neuropharm.2019.107748

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191

  Yildirim SimsirI.SoyaltinU. E.CetinkalpS. (2018). Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease.Diabetes Metab. Syndr.12469–475. 10.1016/j.dsx.2018.03.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  ZhaiR.XuH.HuF.WuJ.KongX.SunX. (2020). Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia-reperfusion injury.Br. J. Pharmacol.1773389–3402. 10.1111/bph.15059

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  ZhangL.ZhangL.LiL.HölscherC. (2018). Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson’s disease mouse model.Neuropeptides7170–80. 10.1016/j.npep.2018.07.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  ZhangL.ZhangL.LiL.HölscherC. (2019). Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease.J. Parkinsons. Dis.9157–171. 10.3233/JPD-181503

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  ZhouM.WangW.HuangW.ZhangX. (2014). Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis.PLoS One9:e102972. 10.1371/journal.pone.0102972

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  ZinmanB.ArodaV. R.BuseJ. B.CariouB.HarrisS. B.HoffS. T.et al (2019a). Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: the PIONEER 8 Trial.Diabetes Care422262–2271. 10.2337/dc19-0898

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  ZinmanB.BhosekarV.BuschR.HolstI.LudvikB.ThielkeD.et al (2019b). Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.Lancet Diabetes Endocrinol.7356–367. 10.1016/S2213-8587(19)30066-X

  • CrossRef
  • Google Scholar